Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUICJD)

• Drug Name: SAR-156597 Drug Info
• Synonyms: IL-4/IL-13-targeting bispecific mAb (idiopathic pulmonary fibrosis), sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]
Pulmonary fibrosis	CB03.4	Phase 2	[2]
Systemic sclerosis	4A42	Phase 2	[3]

• Cross-matching ID: TTD Drug ID: DMUICJD

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-4 (IL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[6]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[7]
Tepoxalin	DMVS61L	Asthma	CA23	Phase 2	[8]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[9]
IL-4R	DMYEGRH	N. A.	N. A.	Phase 2	[10]
Pascolizumab	DMU3XJP	Asthma	CA23	Phase 2	[7]
PF-07264660	DM0GI2H	Atopic dermatitis	EA80	Phase 1	[11]
PF-07275315	DMHRVUY	Atopic dermatitis	EA80	Phase 1	[11]

Drug(s) Targeting Interleukin 4 receptor alpha (IL4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dupilumab	DMOAD2Y	Atopic dermatitis	EA80	Approved	[12]
SAR231893	DMHFBOG	Asthma	CA23	Phase 3	[12]
CBP-201	DMWYNN1	Atopic dermatitis	EA80	Phase 3	[13]
Aerovant	DMUB8WN	Asthma	CA23	Phase 2a	[14]
PRX-321	DM7YWVT	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
Altrakincept	DMLSK01	Asthma	CA23	Phase 2	[7]
AZD1402	DM73O6I	Asthma	CA23	Phase 2	[16]
AMG 317	DMUO3T2	Asthma	CA23	Discontinued in Phase 1	[17]
PRS-060	DM8GCHX	Asthma	CA23	Investigative	[4]
APG-201	DM0BVJN	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]

Drug(s) Targeting Interleukin-13 (IL13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tralokinumab	DM6ENSJ	Atopic dermatitis	EA80	Approved	[3]
Lebrikizumab	DMQP0X5	Severe asthma	CA23	Phase 3	[7]
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[6]
Cendakimab	DM9LSBJ	Eosinophilic esophagitis	DA24.1	Phase 3	[18]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[7]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[9]
QAX-576	DMUWFI7	Allergic rhinitis	CA08.0	Phase 2	[19]
Anrukinzumab	DMTG2O0	Asthma	CA23	Phase 2	[20]
Dectrekumab	DM1H7UK	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[19]
CNTO-5825	DMF8WAT	Allergic asthma	CA23.0	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 4 receptor alpha (IL4R)	TTDWHC3	IL4RA_HUMAN	Not Available	[4]
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Modulator	[5]
Interleukin-4 (IL4)	TTLGTKB	IL4_HUMAN	Modulator	[5]

References

• [1] ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034106)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
• [5] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [6] Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
• [7] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [8] Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
• [9] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
• [10] Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
• [11] Clinical pipeline report, company report or official report of Pfizer
• [12] Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
• [13] Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Ralpha, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023 Jul 31;13(1):12411.
• [14] Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009.
• [15] Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther. 2009 Aug;330(2):520-5.
• [16] Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma. J Allergy Clin Immunol. 2023 Apr;151(4):966-975.
• [17] Clinical pipeline report, company report or official report of Amgen (2009).
• [18] Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
• [19] Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
• [20] Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
• [21] Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.